Neogenomics (NEO) Accumulated Expenses (2010 - 2026)

Neogenomics (NEO) has 17 years of Accumulated Expenses data on file, last reported at $56.3 million in Q2 2026.

• Quarterly Accumulated Expenses rose 15.87% year-over-year to $56.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $56.3 million (up 15.87% YoY) and the FY2025 annual result came in at $47.6 million, down 23.8% from the prior year.
• Accumulated Expenses improved to $56.3 million in Q2 2026, from $40.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $62.4 million in Q4 2024 to a low of $32.3 million in Q1 2022.
• A 5-year average of $45.1 million and a median of $46.6 million in 2023 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 36.83% — and 2025, when it declined 23.8%.
• Tracing NEO's Accumulated Expenses over 5 years: stood at $40.1 million in 2022, then soared by 32.44% to $53.2 million in 2023, then increased by 17.46% to $62.4 million in 2024, then slipped by 23.8% to $47.6 million in 2025, then increased by 18.25% to $56.3 million in 2026.
• The last three Accumulated Expenses figures came in at $56.3 million (Q2 2026), $40.6 million (Q1 2026), and $47.6 million (Q4 2025), per Business Quant data.